2-(4-hydroxy-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one | 76858-78-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(4-hydroxy-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one
• 英文别名: 5-methyl-4-phenyl-2-(4-hydroxyphenyl)-3-pyrazolone；1-(4-Hydroxyphenyl)-3-methyl-2-pyrazolin-5-one；2-(4-Hydroxyphenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one；2-(4-hydroxyphenyl)-5-methyl-4H-pyrazol-3-one
• CAS: 76858-78-1
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: UAJMXYVLALDCCI-UHFFFAOYSA-N

物化性质

• 熔点：
  230 °C (decomp)
• 沸点：
  429.5±28.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxy-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one 、 二乙二醇双对甲苯磺酸酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以46%的产率得到1,7'-bis[4-(3-methyl-2,3-dihydro-pyrazol-1-yl)phenol]-1,4,7-trioxaheptane
  参考文献：
  名称：

  Synthesis, Structure and Supramolecular Properties of 1,7'-bis[4-(3-Methyl-2,3-dihydro-pyrazol-1-yl)phenol]-1,4,7-trioxaheptane

  摘要：

  一种新的吡唑衍生物，1,7-双[4-(3-甲基-2,3-二氢吡唑-1-氮基)苯酚]-1,4,7-三氧杂庚烷，分子式C24H24N4O5已被合成，其晶体结构通过单晶X射线衍射法确定。有趣的是，标题化合物通过分子间O2–H22···N2氢键连接成一个36个原子的宏环，并通过另一个酚氧原子与一个亚甲基碳原子之间的C–H···O氢键进一步结合形成一维珠链。

  DOI：

  10.14233/ajchem.2015.17871
• 作为产物：
  描述：

  1-(4-甲氧基)苯基-3-甲基-5-吡唑啉酮 在 氢溴酸 、 溶剂黄146 作用下， 生成 2-(4-hydroxy-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one
  参考文献：
  名称：

  Synthesis, Structure and Supramolecular Properties of 1,7'-bis[4-(3-Methyl-2,3-dihydro-pyrazol-1-yl)phenol]-1,4,7-trioxaheptane

  摘要：

  一种新的吡唑衍生物，1,7-双[4-(3-甲基-2,3-二氢吡唑-1-氮基)苯酚]-1,4,7-三氧杂庚烷，分子式C24H24N4O5已被合成，其晶体结构通过单晶X射线衍射法确定。有趣的是，标题化合物通过分子间O2–H22···N2氢键连接成一个36个原子的宏环，并通过另一个酚氧原子与一个亚甲基碳原子之间的C–H···O氢键进一步结合形成一维珠链。

  DOI：

  10.14233/ajchem.2015.17871

文献信息

• Synthesis and reactions of 4-isopropylidene-1-aryl-3-methyl-2-pyrazolin-5-ones
  作者：Jack Deruiter、Deborah Ann Carter、Wilmer Scott Arledge、Patrick J. Sullivan

  DOI：10.1002/jhet.5570240128

  日期：1987.1

  or piperidine, 4a-d failed to yield conjugate addition products, presumably due to the steric bulk provided by the two methyl substituents of the isopropylidene side chain. Reaction of 4a-d with hydrazine derivatives gave the 1-aryl-3-methyl-2-pyrazolin-5-ones 3a-d and isopropyl-hydrazones. Treatment of 4a with potassium cyanide yielded a stable conjugate addition product which exists as a mixture of

  在各种条件下研究了4-异亚丙基-1-芳基-3-甲基-2-吡唑啉-5-酮4a-d的反应。在硫醇或哌啶的存在下，4a-d未能产生共轭加成产物，这可能是由于异亚丙基侧链的两个甲基取代基所提供的空间体积。4a-d与肼衍生物反应，得到1-芳基-3-甲基-2-吡唑啉-5-酮3a-d和异丙基hydr。用氰化钾处理4a得到稳定的共轭加成产物，其以互变异构体的混合物形式存在于不同溶剂中。此外，用过氧化氢氧化4a可获得螺环氧化物22，而间氯过苯甲酸氧化既提供了螺环氧化物22，又提供了少量的羟基螺环氧化物23。
• PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1553087A1

  公开（公告）日：2005-07-13

  The object of the present invention is to provide a medicament useful for preventing and/or treating inflammatory bowel disease. The present invention provides a medicament for preventing and/or treating inflammatory bowel disease which comprises as an active ingredient a pyrazolone derivative represented by the following formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof: wherein R1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R1 and R2 are combined with each other to represent an alkylene group; and R3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.

  本发明的目的是提供一种用于预防和/或治疗炎性肠病的药物。本发明提供了一种药物，用于预防和/或治疗炎性肠病，其包括以下式（I）所表示的吡唑酮衍生物作为活性成分，或其生理上可接受的盐，或其水合物或溶剂化合物：其中R1表示氢原子，芳基，烷基或烷氧羰基烷基；R2表示氢原子，芳氧基，芳硫基，烷基或羟基烷基；或R1和R2结合在一起表示烷基；R3表示氢原子，烷基，环烷基，羟基烷基，苄基，萘基，苯基或苯基，其被1至3个取代基所取代，所述取代基被选自羟基烷基，烷氧基，羟基烷氧基，烷氧羰基，烷硫基，烷基氨基，二烷基氨基，卤素原子，三氟甲基基团，羧基，氰基，羟基，硝基，氨基和乙酰胺基。
• AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20170273949A1

  公开（公告）日：2017-09-28

  It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof.

  本发明的目的是提供一种新型药物，用于预防和/或治疗由眼部血管生成引起的眼科疾病。根据本发明，提供了一种用于预防和/或治疗由眼部血管生成引起的眼科疾病的药物，其包括作为活性成分的吡唑酮衍生物，如3-甲基-1-苯基-2-吡唑啉-5-酮，或其生理上可接受的盐，或其水合物或溶剂化物。
• Medicament for prevention and/or therapy of arterial wall disorder
  申请人：——

  公开号：US20040254234A1

  公开（公告）日：2004-12-16

  An object of the present invention is to provide a medicament and method which is useful for prevention and/or therapy of arterial wall injury. According to the present invention, there is provided a method for prevention and/or therapy of arterial wall injury which comprises a step of administering the pyrazolone derivative represented by the following formula (I) or the physiologically acceptable salt thereof, or the hydrate or solvate thereof in a preventively or therapeutically effective amount to mammals including humans: 1 wherein R 1 represents a hydrogen atom, an aryl group, an alkyl group, or an alkoxycarbonylalkyl group; R 2 represents a hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group or a hydroxyalkyl group; or R 1 and R 2 are combined with each other to represent an alkylene group; and R 3 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a benzyl group, a naphthyl group, a phenyl group, or a phenyl group substituted with 1 to 3 substituents selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkylmercapto group, an alkylamino group, a dialkylamino group, a halogen atom, a trifluoromethyl group, a carboxyl group, a cyano group, a hydroxyl group, a nitro group, an amino group and an acetamide group.

  本发明的目的是提供一种药物和方法，用于预防和/或治疗动脉壁损伤。根据本发明，提供了一种预防和/或治疗动脉壁损伤的方法，包括向哺乳动物，包括人类，预防性或治疗性地给予以下式（I）所表示的吡唑酮衍生物或其生理上可接受的盐，或其水合物或溶剂，以预防或治疗有效量：1其中R1表示氢原子，芳基，烷基或烷氧羰基烷基；R2表示氢原子，芳氧基，芳硫醇基，烷基或羟基烷基；或R1和R2结合在一起表示烷基；R3表示氢原子，烷基，环烷基，羟基烷基，苄基，萘基，苯基或苯基，其被1至3个取自羟基烷基，烷氧基，烷氧羰基基，烷硫基，烷基氨基，二烷基氨基，卤素原子，三氟甲基基，羧基，氰基，羟基，硝基，氨基和乙酰胺基的取代基所取代。
• 一种用于治疗脑卒中的含氧杂环化合物
  申请人：深圳市第二人民医院（深圳市转化医学研究院）

  公开号：CN112209920B

  公开（公告）日：2023-05-16

  本发明涉及一种预防和治疗脑卒中特别是缺血性脑卒中的化合物，其在小鼠脑缺血再灌注试验中，显示出良好的治疗活性，其能够显著降低脑梗塞比例，能够用于预防和治疗脑卒中特别是缺血性脑卒中。